$LIVN News
Last published 2d ago
- 2d agoLIVNLivaNova - 1780179 - LIVANOVA PLCEarnings Call TranscriptsWelcome. With me today is Alex Worshberg and Phil Kowalczyk, CFO and Head of Strategy and EVP from Levenova. My name is Ben Bible. Pleasure to be speaking with you all at the Global Healthcare Conference here in Palm Bea
- 2d agoLIVNLivaNova - 1780179 - LIVANOVA PLCEarnings Call TranscriptsWelcome. With me today is Alex Worshberg and Phil Kowalczyk, CFO and Head of Strategy and EVP from Levenova. My name is Ben Bible. Pleasure to be speaking with you all at the Global Healthcare Conference here in Palm Bea
- 2d agoLIVNUBS Global Healthcare Conference - LIVANOVA PLCEarnings Call TranscriptsWelcome. With me today is Alex Worshberg and Phil Kowalczyk, CFO and Head of Strategy and EVP from Levenova. My name is Ben Bible. Pleasure to be speaking with you all at the Global Healthcare Conference here in Palm Bea
- 1w agoLIVNLivaNova PLC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoLIVNNeuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant EpilepsyBusiness Wire– CORE-VNS is the largest prospective, multinational observational study evaluating contemporary VNS Therapy devices in people with Drug-Resistant Epilepsy – Demonstrated 76% median reduction in seizure frequency and a
- 3w agoLIVNLivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in NovemberBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that members of the Company’s Executive Leadership Team will provide general business updates during fireside chats at the four
- 1mo agoLIVNLivaNova to Announce Third-Quarter 2026 ResultsBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern
- 1mo agoLIVNBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - LIVANOVA PLCEarnings Call TranscriptsWell, I think we're all set to get started. Thanks, everyone, for joining. I'm Dave Rescott, Senior MedTech Analyst here at Baird. Happy to have the LevaNova team here with us. We've got Vlad, the CEO. We've Got Alex, th
- 1mo agoLIVNBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - LIVANOVA PLCEarnings Call TranscriptsWell, I think we're all set to get started. Thanks, everyone, for joining. I'm Dave Rescott, Senior MedTech Analyst here at Baird. Happy to have the LevaNova team here with us. We've got Vlad, the CEO. We've Got Alex, th
- 1mo agoLIVNLivaNova - 1773716 - LIVANOVA PLCEarnings Call TranscriptsPerfect. I think we'll get going here. First, just an administrative thing, there is a disclaimer on the Morgan Stanley website, so please make sure to go look at that. I'm very happy to welcome back the Leva Nova team t
- 1mo agoLIVNLivaNova 1773716 - LIVANOVA PLCEarnings Call TranscriptsPerfect. I think we'll get going here. First, just an administrative thing, there is a disclaimer on the Morgan Stanley website, so please make sure to go look at that. I'm very happy to welcome back the Leva Nova team t
- 2mo agoLIVNLivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in SeptemberBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City: Morgan Stanley 24th Annual Global
- 3mo agoLIVNLivaNova 2Q 2026 Earnings Call - LIVANOVA PLCEarnings Call TranscriptsGood day, ladies and gentlemen, and welcome to the LevaNova PLC Second Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please p
- 3mo agoLIVNLivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS GuidanceBusiness Wire– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8% – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) – Entered into a
- 4mo agoLIVNLivaNova to Announce Second-Quarter 2026 ResultsBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight
- 4mo agoLIVNLivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep ApneaBusiness Wire– Presentation at SLEEP 2026 illustrates ability to convert non-responders into responders using personalized programming LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced new
- 5mo agoLIVNJette Nygaard-Andersen Joins LivaNova Board as a New DirectorBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors after its Annual General Meeting of shareholders on June
- 5mo agoLIVNLivaNova Appoints Anne Liddy as Chief Legal OfficerBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company's global legal and
- 5mo agoLIVNLivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business UnitBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti,
- 5mo agoLIVNLivaNova to Present at Goldman Sachs Global Healthcare Conference in JuneBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief
- 6mo agoLIVNLivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS GuidanceBusiness Wire– Delivered double-digit reported and constant-currency revenue growth – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) – Received U.S. Food and Drug Administration premarket
- 6mo agoLIVNAnnals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep ApneaBusiness Wire– Study demonstrates proximal hypoglossal nerve stimulation (pHGNS) yielded clinically significant responses and sustained improvements over time – First rigorous RCT study design in HGNS space supports pHGNS becoming
- 7mo agoSENSMBOTLIVNCLOVMedTech's Edge: How AI and Remote Diagnostics Drive Scalable ValuePR NewswireEquity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory...
- 7mo agoLIVNLivaNova to Announce First-Quarter 2026 ResultsBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time).
- 7mo agoLIVNLivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep ApneaBusiness Wire– First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language – Next-generation, MRI-compatible device expected to launch in the
- 8mo agoLIVNLivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 GuidanceBusiness Wire– Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and
- 10mo agoLIVNLivaNova to Present at J.P. Morgan Healthcare Conference in JanuaryBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive
- 11mo agoLIVNLivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual MeetingBusiness WireEight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology
- 11mo agoLIVNLivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep ApneaBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise
- 11mo agoLIVNLivaNova to Present at Piper Sandler Healthcare Conference in DecemberBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler
- 11mo agoLIVNLivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid ServicesBusiness Wire– New patient implants assigned to New Technology Ambulatory Payment Classification 1580 – End-of-service procedures elevated to Level 5 APC – Effective Jan. 1, 2026, will improve economics for hospitals performing
- 12mo agoLIVNLivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor DayBusiness WireProvides 2030 Targets for Revenue and EPS Growth LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and
- 1y agoLIVNLivaNova Reports Third-Quarter 2025 Results; Raises 2025 GuidanceBusiness Wire– Delivered double-digit reported and organic revenue growth and continued operating margin expansion – Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1) – Launched
- 1y agoLIVNLivaNova to Present at Wolfe Research Healthcare Conference in NovemberBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business
- 1y agoLIVNLivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual MeetingBusiness WireCompany studies continue to show durability and retention of benefits for patients receiving proximal hypoglossal nerve stimulation for moderate to severe obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a
- 1y agoLIVNLivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoLIVNLivaNova Appoints Donald Zurbay as a New DirectorBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of Directors, effective today. Zurbay will serve on the Audit and
- 1y agoLIVNLivaNova to Host Investor Day on November 12, 2025Business WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025, beginning at 9 a.m. EST until approximately 1 p.m. EST
- 1y agoLIVNLivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in SeptemberBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present a general business
- 1y agoLIVNLivaNova Launches Essenz Perfusion System in ChinaBusiness WireNext-generation cardiopulmonary platform surpasses 100,000 patients supported worldwide since 2023 launch LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it initiated the
- 1y agoLIVNLivaNova PLC (LIVN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoLIVNLivaNova Reports Second-Quarter 2025 Results; Raises 2025 GuidanceBusiness WireDelivered double-digit reported and organic revenue growth and continued operating margin expansion Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1) Initiated
- 1y agoLIVNLivaNova to Announce Second-Quarter 2025 ResultsBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m. Eastern Daylight
- 1y agoLIVNCORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant EpilepsyBusiness WireLong-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced
- 1y agoLIVNLivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant EpilepsyBusiness WireThis is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month
- 1y agoLIVNLivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant DepressionBusiness WireFinal critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS
- 1y agoLIVNLivaNova to Present at the Jefferies Global Healthcare ConferenceBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in
- 1y agoLIVNLivaNova Reports First-Quarter 2025 Results; Updates 2025 GuidanceBusiness WireDelivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates
- 1y agoLIVNLivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of TherapyBusiness WireTop-line results at 12 months of treatment show meaningful improvement over time: Overall responder rate of 65% Overall reduction in median apnea-hypopnea index of 68% Overall reduction in median oxygen desaturation
- 1y agoLIVNLivaNova to Announce First-Quarter 2025 ResultsBusiness WireLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The